GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Roivant Sciences Ltd.
Roivant Sciences is a unique pharmaceutical company that acquires and develops promising, yet "forgotten" drugs. Its stock price reflects its clinical trial successes and its team's ability to identify hidden gems in the biotech world.
Share prices of companies in the market segment - Pharma holding
Roivant is a unique pharmaceutical company that acquires and develops promising but "forgotten" drugs. We classify it as a pharmaceutical holding company. The chart below shows the overall dynamics of this sector, where expertise in asset selection is crucial.
Broad Market Index - GURU.Markets
Roivant Sciences is a biopharmaceutical company that builds and manages a portfolio of subsidiaries ("vants"), each focused on a specific area of medicine. As a unique holding company, it is included in the GURU.Markets index. The chart below shows the dynamics of the entire market. Compare its shares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ROIV - Daily change in the company's share price Roivant Sciences Ltd.
For Roivant, a unique pharmaceutical company developing a portfolio of "vant" drugs, daily price changes are a measure of its reaction to clinical trial news. The graph of these fluctuations is unspectacular, but they are an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma holding
Roivant Sciences Ltd. is a unique biotech holding. This chart demonstrates the sector's high volatility. Comparing it to the ROI dynamics of a company that creates subsidiaries to develop individual drugs helps evaluate its innovative yet risky business model.
Daily change in the price of a broad market stock, index - GURU.Markets
Roivant Sciences is a unique biopharmaceutical company that acquires and develops promising but neglected drugs. Its diversified model aims to mitigate risks in the volatile biotech sector. The chart below reflects average fluctuations in this industry, providing context for evaluating Roivant shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Roivant Sciences Ltd.
Roivant is a unique biotech company that acquires and develops promising but neglected drugs from other companies. Its year-over-year performance reflects the success of its diverse portfolio and its ability to uncover hidden gems.
Annual dynamics of market capitalization of the market segment - Pharma holding
Roivant Sciences Ltd. is a unique pharmaceutical company that doesn't conduct its own research from scratch, but acquires and develops promising but "forgotten" drugs from other companies. This model allows the company to diversify risks. The chart below shows how the market views its innovative approach to drug development.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Roivant Sciences is a unique pharmaceutical company that acquires and develops promising, yet "forgotten" drugs. Its growth is driven by the clinical trial successes of its subsidiaries (Vants). It is a diversified bet on biotech innovation.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Roivant Sciences Ltd.
The performance of Roivant Sciences, a pharmaceutical holding company with a unique business model, depends on R&D news. Monthly fluctuations on the chart reflect not sales, but rather progress in clinical trials of drugs at its subsidiaries, the successful results of which could lead to a sharp increase in value.
Monthly dynamics of market capitalization of the market segment - Pharma holding
This chart reflects the dynamics of the biotech sector. For Roivant, with its unique drug development model, it's the backdrop. Its movements demonstrate how the commercial success of its drugs and progress in its extensive R&D pipeline allow it to outpace expectations.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Roivant Sciences is a unique biotech holding company that creates spin-off companies (called "spinoffs") to develop promising, yet "forgotten" drugs. Its performance is the sum of the histories of its startups. Against the backdrop of market trends shown in the chart, Roivant shares are driven by news of clinical trials across its broad portfolio.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Roivant Sciences Ltd.
Roivant Sciences is a pharmaceutical company with a unique incubator model for drug development. Its shares exhibit high weekly volatility, responding to news from its subsidiary portfolio, trial data, and partnerships.
Weekly dynamics of market capitalization of the market segment - Pharma holding
Roivant Sciences is a pharmaceutical holding company with a unique drug development model. Comparing its weekly performance with the biotech sector will reveal how the market views its approach. The chart shows whether the company is outperforming the industry due to success in its diversified project portfolio.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Roivant Sciences, a pharmaceutical holding company, exist in a world of their own, far removed from macroeconomic news. Their performance is determined by news from their development portfolio. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
ROIV - Market capitalization of the company Roivant Sciences Ltd.
Roivant Sciences' market capitalization reflects an innovative drug development model based on the creation of subsidiaries for individual projects. The chart shows how the market views this "biotech pipeline" approach. Its dynamics depend on developments across the entire development pipeline, making it a story about risk management in the pharmaceutical industry.
ROIV - Share of the company's market capitalization Roivant Sciences Ltd. within the market segment - Pharma holding
Roivant Sciences is a pharmaceutical company with a unique model: it creates spin-off companies ("vants") to develop promising drugs. Its sector weighting reflects investors' confidence in its ability to identify and develop innovative assets. The chart below shows how the market assesses the weighting of its diversified portfolio of biotech startups.
Market capitalization of the market segment - Pharma holding
Roivant Sciences builds and launches biotech companies ("Vants") using an innovative drug development model. The chart below shows the total market capitalization of the pharmaceutical sector. It helps to understand the scale of the industry that Roivant is trying to transform with its approach to research and development.
Market capitalization of all companies included in a broad market index - GURU.Markets
This visualizes an innovative model in pharmaceuticals. Roivant Sciences doesn't invent drugs from scratch, but rather discovers and develops promising but "forgotten" developments from other companies. Its valuation line reflects the success of this venture strategy, which has the potential to dramatically accelerate the development of new treatments.
Book value capitalization of the company, segment and market as a whole
ROIV - Book value capitalization of the company Roivant Sciences Ltd.
Roivant Sciences' equity is its investment in a portfolio of subsidiary biotech companies, each developing its own drugs. The book value reflects the valuation of these stakes and the accumulated financial reserves. The chart below shows how this "holding" equity has changed depending on the successes and failures of the portfolio's clinical trials.
ROIV - Share of the company's book capitalization Roivant Sciences Ltd. within the market segment - Pharma holding
Roivant Sciences is an incubator for new drug development, not a giant manufacturer. The company uses a flexible model, creating spinoff startups, and doesn't own large manufacturing facilities. The chart shows a minimal share of physical assets, as its value lies in its pipeline of promising developments, not its production capacity.
Market segment balance sheet capitalization - Pharma holding
Roivant Sciences, as a pharmaceutical holding company, operates a hybrid model. The company itself is lightweight, but its subsidiaries may own laboratories and R&D centers. The biotech sector's BCap_Seg chart serves as a backdrop to its strategy of betting on intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Roivant Sciences' capital is not represented by production lines, but rather a portfolio of investments in biotech subsidiaries, each of which owns patents and clinical trial data. The book value reflects the capital invested in scientific research. The chart shows how this "venture" approach compares to the assets of large pharmaceutical companies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Roivant Sciences Ltd.
Roivant's balance sheet isn't its factories, but rather its capital invested in a portfolio of biotech subsidiaries. Its market valuation reflects its belief in its unique model of rapidly discovering, developing, and bringing promising drugs to market. The chart shows how investors value this "incubator" for pharmaceutical innovation.
Market to book capitalization ratio in a market segment - Pharma holding
Roivant Sciences has a unique business model: it discovers and develops promising drugs through its subsidiaries. Its value lies in its intellectual property portfolio and the potential of its developments. The chart reflects investors' confidence in its ability to successfully commercialize scientific discoveries.
Market to book capitalization ratio for the market as a whole
Roivant Sciences is a pharmaceutical company that discovers and develops promising drugs. Its model is based on intellectual assets, not manufacturing. Its market capitalization reflects the value of its development pipeline and investors' confidence in the success of clinical trials, significantly exceeding its modest book value.
Debts of the company, segment and market as a whole
ROIV - Company debts Roivant Sciences Ltd.
Roivant Sciences, a pharmaceutical company with a unique subsidiary-based drug development model ("Vants"), uses debt to finance a diverse clinical trial portfolio. Debt capital allows the company to diversify risk across multiple projects. This chart shows how the holding company manages its finances to advance multiple drug candidates.
Market segment debts - Pharma holding
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiaries ("Vants") to develop promising drugs. Its debt policy can be complex, reflecting the funding of an entire portfolio of biotech startups. This chart helps assess how centralized and aggressively Roivant uses debt to support its many projects.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Roivant Sciences Ltd.
Roivant Sciences is a pharmaceutical company with a unique model of drug development through subsidiaries. This chart shows how it finances its diverse portfolio of biotech projects. Its debt level reflects its risk appetite and its reliance on the success of clinical trials to repay these liabilities.
Market segment debt to market segment book capitalization - Pharma holding
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiaries to develop promising drugs. Financing this pipeline of startups may require debt. The chart shows how this innovative company's debt load compares to the overall market capitalization of the pharmaceutical industry.
Debt to book value of all companies in the market
Roivant Sciences, a pharmaceutical holding company, finances a portfolio of biotech startups. This chart allows us to assess the total debt burden of this innovative model in a broader context, comparing it to the overall market capitalization and leverage ratios of the entire stock market.
P/E of the company, segment and market as a whole
P/E - Roivant Sciences Ltd.
Roivant Sciences is a pharmaceutical company that creates subsidiary companies ("vants") to develop and commercialize promising drugs. This chart shows how investors view its unique business model. The metric's dynamics reflect not so much current sales as their belief in Roivant's ability to identify and successfully develop innovative medical projects.
P/E of the market segment - Pharma holding
Roivant Sciences has a unique model for creating spinoffs for drug development. This chart shows the average valuation for the biotech sector. It helps understand how the market values this innovative yet complex structure: whether it offers a premium for risk diversification or a discount for management complexity.
P/E of the market as a whole
Roivant Sciences builds its business on discovering and developing promising, yet "forgotten" by other companies, drugs. This unique model in the pharmaceutical industry is similar to a venture capital fund. This chart reflects the overall risk appetite in biotech. It's important for Roivant, as market sentiment influences the valuation of its portfolio and the ability to profitably IPO its subsidiaries.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Roivant Sciences Ltd.
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiary companies ("vants") to develop promising drugs. This chart reflects the combined investor expectations for clinical trial success across its numerous projects. The trend represents an assessment of the potential of the entire pipeline.
%20P%2FE%20Roivant%20Sciences%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Roivant-Sciences-Ltd.&v=1772513792128 "Chart of the company's future (projected) P/E Roivant Sciences Ltd.")
Future (projected) P/E of the market segment - Pharma holding
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiary companies ("vants") to develop promising drugs. This chart shows the profitability expectations for pharmaceutical holdings. It allows us to assess the market's confidence in the effectiveness of this approach to R&D and Roivant's ability to bring successful drugs to market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772513792150 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
Roivant Sciences is a pharmaceutical company that creates spin-off companies (subsidiaries) to develop and commercialize promising drugs. This chart shows investors' risk appetite. For an innovative biotech company with a unique business model, it demonstrates the market's willingness to fund research with an uncertain but potentially high outcome.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513792184 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Roivant Sciences Ltd.
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiaries ("Vants") to develop promising drugs. The financial results, reflected in the graph, often include revenue from the sale of stakes in these companies or from partnerships. It demonstrates the results of its strategy for rapid drug development and commercialization through a flexible structure.
Profit of companies in the market segment - Pharma holding
Roivant Sciences is a pharmaceutical company with a unique model: it creates spinoffs ("Vants") to develop promising but undervalued drug candidates. Its success depends on the effectiveness of its R&D and acquisitions. This chart reflects the dynamics of the biotech sector, where innovative approaches to drug development like Roivant's can lead to breakthroughs.
Overall market profit
Roivant Sciences is a pharmaceutical company that builds subsidiary companies (subsidiaries) to develop promising drugs. Its success depends on breakthroughs in research and the ability to attract capital. Investments in biotechnology of this kind require excess liquidity in the market, which occurs during periods of strong economic growth, as reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Roivant Sciences Ltd.
Roivant Sciences is a biopharmaceutical company with a unique model: it creates subsidiaries ("Vants") to develop promising drugs. The revenue forecast in this chart reflects analysts' expectations for clinical trial success in the portfolio of these "Vants" and for potential partnerships or sales of developed assets.
%20profit%20of%20the%20company%20Roivant%20Sciences%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Roivant-Sciences-Ltd.&v=1772513792345 "Graph of future (projected) profit of the company Roivant Sciences Ltd.")
Future (predicted) profit of companies in the market segment - Pharma holding
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiaries ("Vants") to develop promising but undervalued drugs. This innovative approach to R&D is a testament to Roivant's success. This chart shows the profit projections for pharmaceutical holding companies, helping to assess how successful Roivant's decentralized strategy is compared to traditional giants.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772513792349 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
Roivant Sciences is a biopharmaceutical company that develops and commercializes drugs through its subsidiaries (Vants). Its success depends on the results of clinical trials and its ability to raise capital. This chart, reflecting market sentiment, influences the investment climate in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513792351 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Roivant Sciences Ltd.
Roivant Sciences builds its business on discovering and developing promising but "forgotten" drugs from other pharmaceutical companies. This chart shows how investors value its revenue, which can be volatile and dependent on the success of individual projects. This trend reflects confidence in its unique R&D model and future blockbusters.
P/S market segment - Pharma holding
Roivant Sciences is a pharmaceutical company focused on identifying, developing, and commercializing promising drugs through its subsidiaries ("Vants"). Its model is focused on accelerating drug delivery to market. This chart shows how investors view Roivant's innovative approach to drug development compared to traditional pharmaceutical companies.
P/S of the market as a whole
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiaries ("Vants") to develop promising drugs that have been shelved by other companies. This innovative approach to R&D carries its own risks. This chart helps understand how the market values unconventional biotech business models against the backdrop of overall healthcare revenue valuations.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Roivant Sciences Ltd.
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiaries (Vants) to develop promising drugs. This chart shows how the market values the company relative to its future sales and research success. It reflects investor expectations for successful clinical trials in its pipeline.
%20P%2FS%20Roivant%20Sciences%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Roivant-Sciences-Ltd.&v=1772513792483 "The graph of the company's future (projected) P/S Roivant Sciences Ltd.")
Future (projected) P/S of the market segment - Pharma holding
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiaries ("Vants") to develop promising drugs that have been shelved by other pharma giants. This approach allows for risk diversification. This chart shows how the market views its portfolio potential and future sales compared to traditional biopharma companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772513792494 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
Roivant Sciences is a biopharmaceutical company that creates spin-off companies (called "spinoffs") to develop promising drugs. Its success depends on the results of clinical trials and strategic deals. This ROIV chart is not a direct driver. The company's value is determined by the potential of its pipeline, not the current economic climate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513792524 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Roivant Sciences Ltd.
This chart illustrates the complex operating model of the biopharmaceutical company Roivant Sciences. It reflects revenues from sales of drugs already on the market, as well as royalties and milestone payments from partners as various drugs in its extensive pipeline are successfully advanced.
Sales of companies in the market segment - Pharma holding
Roivant Sciences is a pharmaceutical company that creates spinoffs ("Vants") to develop promising drugs. Its success depends on its ability to identify and develop assets, often acquired from large pharmaceutical companies. This chart illustrates how Roivant's innovative R&D model and clinical trial results are impacting the entire biotech sector.
Overall market sales
Roivant Sciences is a pharmaceutical company with a unique model: it discovers and develops promising, yet neglected, drugs. Its success depends on the effectiveness of its R&D and its ability to bring new drugs to market. It exemplifies an innovative approach in healthcare, one of the largest sectors in the modern economy.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Roivant Sciences Ltd.
Roivant Sciences is a pharmaceutical company with a unique model: it creates spin-off companies (or spin-offs) to develop promising, but "forgotten" drugs. Future sales forecasts depend on the success of clinical trials across its diverse pipeline. This chart reflects the combined expectations for numerous innovative projects.
%20sales%20of%20the%20company%20Roivant%20Sciences%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Roivant-Sciences-Ltd.&v=1772513792760 "Schedule of future (projected) sales of the company Roivant Sciences Ltd.")
Future (projected) sales of companies in the market segment - Pharma holding
Roivant Sciences is building subsidiaries ("vants") to develop promising drugs. The forecast for the pharmaceutical holding company sector reflects overall investment sentiment and allows us to assess the success of Roivant's business model for rapidly commercializing scientific developments in the current market conditions.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772513792856 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
Roivant Sciences is a pharmaceutical company that creates subsidiaries to develop and commercialize promising drugs. Its success depends on the results of clinical trials, not on general economic trends. However, the economic situation, as reflected here, influences the availability of venture capital and the mood in the biotech market, which is important for funding.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513792913 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Roivant Sciences Ltd.
Roivant Sciences, a pharmaceutical company with an innovative drug development model through subsidiary "vant" companies, demonstrates its approach to R&D management in this diagram. Profitability depends on the success of clinical trials and subsequent commercialization or sale of rights to the developed drugs, which can lead to significant fluctuations in profits.
Market segment marginality - Pharma holding
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiaries (Vants) to develop promising but "forgotten" drugs. This chart reflects the average profitability in the pharmaceutical industry. The success of this strategy and the ability to outperform the industry depend on the ability to identify valuable assets and effectively manage their development.
Market marginality as a whole
Roivant Sciences Ltd. is a biopharmaceutical company with a unique model: it creates spin-off companies ("spinoffs") to develop promising drugs acquired from other companies. This chart shows average profitability. Against this backdrop, Roivant demonstrates an innovative approach to R&D management, striving to improve the efficiency of drug development and their potential profitability.
Employees in the company, segment and market as a whole
Number of employees in the company Roivant Sciences Ltd.
Roivant Sciences is a pharmaceutical company that builds subsidiaries ("Vants") to develop promising drugs. Its model involves a relatively lean central team. The dynamics in this chart reflect the activity of creating and funding new "Vants," as well as progress in their clinical programs, which is the core of its strategy.
Share of the company's employees Roivant Sciences Ltd. within the market segment - Pharma holding
Roivant Sciences has a unique business model: it acquires or licenses promising but "forgotten" developments from large pharmaceutical companies and creates subsidiaries ("Vants") to develop them. This chart shows its organizational structure. It reflects the proportion of scientists and managers specializing in accelerated drug development that Roivant employs.
Number of employees in the market segment - Pharma holding
Roivant Sciences is a pharmaceutical company with a unique model: it discovers and develops promising drugs that have been "forgotten" by other companies. This graph shows growth in the innovative but risky biotech sector. The company's success creates jobs for scientists and managers who can recognize hidden potential in science.
Number of employees in the market as a whole
Roivant Sciences is a pharmaceutical company that builds and launches biotech subsidiaries to develop promising drugs. Its model requires significant investment in research. Overall economic stability, illustrated by this chart, influences the availability of venture capital and investors' willingness to fund long-term research projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Roivant Sciences Ltd. (ROIV)
Roivant Sciences is a unique pharmaceutical company that doesn't invent drugs from scratch, but rather discovers and develops promising but "forgotten" discoveries from other companies. This chart demonstrates the effectiveness of its business model. Its high market capitalization per employee demonstrates the ability of its small, elite team to discover and develop hidden gems.
%20of%20the%20company%20Roivant%20Sciences%20Ltd.%20(ROIV)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Roivant-Sciences-Ltd.-ROIV&v=1772513793249 "Chart of market capitalization per employee (in thousands of dollars) of the company Roivant Sciences Ltd. (ROIV)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
Roivant Sciences is a biotech company operating under a hub-and-spoke model: it creates subsidiaries ("Vants") to develop promising, but often forgotten, drugs. This chart shows the industry average cost per employee. It helps assess how much the market values Roivant's unique business model of asset selection and R&D management per employee.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772513793302 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
Roivant Sciences is a pharmaceutical company with a unique model: it creates spin-off companies (called "vants") to develop promising but undervalued drugs. This innovative approach to R&D management. This chart illustrates how the market values a holding structure in biotech, where value is created through efficient capital allocation and portfolio management.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513793318 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Roivant Sciences Ltd. (ROIV)
Roivant Sciences is a pharmaceutical company with a unique model. They create subsidiaries ("Vants") around promising drugs that have been "forgotten" by other companies. It's essentially a biotech incubator. This chart demonstrates the effectiveness of their R&D model. It reflects how successfully a small, central team of managers and scientists converts drug development investments into profit.
%20Chart%20Roivant%20Sciences%20Ltd.%20(ROIV)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Roivant-Sciences-Ltd.-ROIV&v=1772513793353 "Company Profit Per Employee (in thousands of dollars) Chart Roivant Sciences Ltd. (ROIV)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
Roivant is a unique "biotech holding." They don't conduct R&D themselves, but create "Vants" (startups) around acquired patents. This chart shows the benchmark for "Pharm Holdings" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of cash in the hopes of one or two mega-successes.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772513793398 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
Roivant Sciences is a pharmaceutical company with a unique model: it creates spinoffs ("spinoffs") to develop promising but undervalued drugs. This allows it to focus its efforts and capital. This graph reflects the venture-based nature of the business, where profitability depends on the success of individual projects and the effectiveness of small, highly specialized teams.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513793455 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Roivant Sciences Ltd. (ROIV)
Roivant Sciences is a biotech company with a unique model: it creates subsidiaries (Vants) to develop promising drugs. This chart reflects the effectiveness of its decentralized approach. While volatile, the revenue per employee figure could potentially indicate the success of commercializing the drugs in its portfolio.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Roivant-Sciences-Ltd.-ROIV&v=1772513793471 "Sales chart per company employee Roivant Sciences Ltd. (ROIV)")
Sales per employee in the market segment - Pharma holding
Roivant Sciences is a pharmaceutical company with a unique model: it creates subsidiary "Vant companies" to develop promising drugs. It's more of an incubator for biotech startups. This metric can be volatile, but it reflects how effectively their management team selects and develops successful projects, generating revenue from partnerships or sales.
Sales per employee for the market as a whole
Roivant Sciences is a biotech company operating under a unique hub-and-spoke model. They create or acquire promising developments (from their Vants subsidiaries), rapidly develop them, and either bring them to market or sell them. This chart shows the revenue generated by their relatively small central staff. It reflects the efficiency of their R&D model, where revenue can fluctuate due to asset sales or royalties.
Short shares by company, segment and market as a whole
Shares shorted by company Roivant Sciences Ltd. (ROIV)
Roivant Sciences operates as a biotech incubator. The company identifies promising but "forgotten" developments from large pharmaceutical companies, creates subsidiary companies called "Vants," and quickly advances them through clinical trials. This chart shows bearish bets. Bears may doubt the effectiveness of this business model, citing past failures and the high risk of clinical trial failure.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Roivant-Sciences-Ltd.-ROIV&v=1772513793575 "Short Shares Chart for the Company Roivant Sciences Ltd. (ROIV)")
Shares shorted by market segment - Pharma holding
Roivant Sciences operates as an incubator, creating spinoff companies ("Vants") to develop promising drugs. This is a high-risk model in biotech. This chart shows the overall short positions in the biotech sector. The high short interest in the industry reflects general market skepticism about the sector, possibly due to trial failures or funding issues.
Shares shorted by the overall market
Roivant (ROIV) is an atypical biotech. It's a holding company that creates startups (Vants) to develop promising drugs. This chart shows the overall level of fear. When pessimism rises, investors fear biotech. Roivant's risk-diversifying model is an attempt to withstand the risk, but the capital drought in the sector is also affecting them.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Roivant Sciences Ltd. (ROIV)
Roivant isn't a biotech company, but a drug incubator. They discover promising molecules and create companies around them. **This chart** measures the reaction to binary events. The success of their key drug (for psoriasis, for example) or the sale of one of the Vantas for billions can cause euphoria, driving **This chart** above 70.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Roivant-Sciences-Ltd.-ROIV&v=1772513793779 "RSI 14 indicator chart for the company's stock Roivant Sciences Ltd. (ROIV)")
RSI 14 Market Segment - Pharma holding
Roivant (ROIV) isn't a traditional pharma company, but a drug incubator. They discover forgotten projects, develop them within their Vant subsidiaries, and bring them to market. This chart shows the overall sentiment in the biotech sector. It helps us understand: is ROIV overheated due to its unique venture-based model, or is it a general overheating of the biotech sector as a whole?
RSI 14 for the overall market
Roivant Sciences (ROIV) is a biotech company that creates subsidiaries called "Vants" to develop promising but "forgotten" drugs. Their business is essentially venture capital in the pharmaceutical industry. This indicator of risk appetite is critical for ROIV. In times of euphoria, investors are willing to fund their model. In times of panic, they demand proven results, and ROIV shares come under pressure.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ROIV (Roivant Sciences Ltd.)
Roivant is a unique biotech company. They don't develop drugs from scratch, but create subsidiary "Vant" companies that license promising but "forgotten" drugs from giants. This chart shows the average 12-month price target from analysts. It reflects their assessment of the company's current blockbusters (Vtama) and the value of their R&D model.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ROIV-Roivant-Sciences-Ltd.&v=1772513793946 "A chart showing analyst consensus forecasts for the expected stock price. ROIV (Roivant Sciences Ltd.)")
The difference between the consensus estimate and the actual stock price ROIV (Roivant Sciences Ltd.)
Roivant Sciences is a unique biopharmaceutical company. They don't invent every drug from scratch, but instead identify promising, neglected assets from others and create subsidiaries (Vants) to rapidly develop them. This chart shows how much analysts believe in their R&D model and recent pipeline successes. It reflects the gap between their target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ROIV-Roivant-Sciences-Ltd.&v=1772513793961 "A chart showing the difference between the consensus forecast and the actual stock price. ROIV (Roivant Sciences Ltd.)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
Roivant Sciences is a drug incubator. The company identifies promising but neglected developments, creates "Vant" subsidiaries for them, and quickly takes them public or sells them. This chart shows analysts' overall expectations across "big pharma." It reflects whether experts believe in this innovative R&D model.
Analysts' consensus forecast for the overall market share price
Roivant Sciences is a unique pharmaceutical holding company. They don't develop everything from scratch, but rather rescue promising projects abandoned by other companies. Market expectations, as seen in this chart, influence the biotech sector. During recessions (pessimism), big pharma often cuts R&D, giving Roivant more opportunities to acquire assets.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Roivant Sciences Ltd.
Roivant Sciences is an atypical biotech company. Rather than conducting early-stage research, they rescue promising but delayed drugs from giants, creating spinoff companies around them for rapid development. This chart is an assessment of their unique R&D model. It measures their ability to select winners and successfully bring them to FDA approval.
AKIMA Market Segment Index - Pharma holding
Roivant Sciences is a unique biotech incubator; the company doesn't seek out drugs from scratch, but rather finds forgotten assets (in R&D at giants) and quickly brings them to market (through Vant companies). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does Roivant's fintech (asset-light) R&D model differentiate it from the average, traditional pharma company?
The AKIM Index for the overall market
Roivant is a unique biotech company. It doesn't do its own R&D, but creates "vant" companies by licensing promising but forgotten drugs from giants. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this deal-based venture capital model compares to general economic trends that influence risk appetite.
